Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma Journal Article
| Authors: | D'Souza, A.; Brazauskas, R.; Stadtmauer, E. A.; Pasquini, M. C.; Hari, P.; Bashey, A.; Callander, N.; Devine, S.; Efebera, Y.; Ganguly, S.; Gasparetto, C.; Geller, N.; Horowitz, M. M.; Koreth, J.; Landau, H.; Brunstein, C.; McCarthy, P.; Qazilbash, M. H.; Giralt, S.; Krishnan, A.; Flynn, K. E. |
| Article Title: | Trajectories of quality of life recovery and symptom burden after autologous hematopoietic cell transplantation in multiple myeloma |
| Abstract: | Early autologous hematopoietic cell transplantation (AHCT) with post-transplant maintenance therapy is standard of care in multiple myeloma (MM). While short-term quality of life (QOL) deterioration after AHCT is known, the long-term trajectories and symptom burden after transplantation are largely unknown. Toward this goal, a secondary analysis of QOL data of the BMT CTN 0702, a randomized controlled trial comparing outcomes of three treatment interventions after a single AHCT (N = 758), was conducted. FACT-BMT scores up to 4 years post-AHCT were analyzed. Symptom burden was studied using responses to 17 individual symptoms dichotomized as ‘none/mild’ for scores 0–2 and ‘moderate/severe’ for scores of 3 or 4. Patients with no moderate/severe symptom ratings were considered to have low symptom burden at 1-year. Mean age at enrollment was 55.5 years with 17% African Americans. Median follow-up was 6 years (range, 0.4–8.5 years). FACT-BMT scores improved between enrollment and 1-year and remained stable thereafter. Low symptom burden was reported by 27% of patients at baseline, 38% at 1-year, and 32% at 4 years post-AHCT. Predictors of low symptom burden at 1-year included low symptom burden at baseline: OR 2.7 (1.8–4.1), p < 0.0001; older age: OR 2.1 (1.3–3.2), p = 0.0007; and was related to being employed: OR 2.1 (1.4–3.2), p = 0.0004). We conclude that MM survivors who achieve disease control after AHCT have excellent recovery of FACT-BMT and subscale scores to population norms by 1-year post-transplant, though many patients continue to report moderate to severe severity in some symptoms at 1-year and beyond. © 2022 Wiley Periodicals LLC. |
| Keywords: | controlled study; middle aged; quality of life; multiple myeloma; randomized controlled trial; hematopoietic stem cell transplantation; transplantation, autologous; adverse event; autotransplantation; humans; human |
| Journal Title: | American Journal of Hematology |
| Volume: | 98 |
| Issue: | 1 |
| ISSN: | 0361-8609 |
| Publisher: | John Wiley & Sons, Inc. |
| Date Published: | 2023-01-01 |
| Start Page: | 140 |
| End Page: | 147 |
| Language: | English |
| DOI: | 10.1002/ajh.26596 |
| PUBMED: | 35567778 |
| PROVIDER: | scopus |
| PMCID: | PMC9659666 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 January 2023 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work